HC Wainwright & Co. Downgrades Catalyst Pharmaceuticals to Neutral, Lowers Price Target to $31.5

Benzinga Newsdesk www.benzinga.com Negative 93.4%

Neg 93.4% Neu 0% Pos 0%

HC Wainwright & Co. analyst Andrew S. Fein downgrades Catalyst Pharmaceuticals (NASDAQ:CPRX) from Buy to Neutral and lowers the price target from $35 to $31.5.